Changes in benign prostatic hyperplasia management in Valencia: A real-world evidence analysis

被引:0
作者
Navarro-Perez, J. [1 ]
Alcina, E. Lopez [2 ]
Perez, J. Calabuig [3 ]
Munto, F. Brotons [4 ]
Martinez, A. [5 ]
Vallejo, L. [6 ]
Jimenez, J. [6 ]
机构
[1] Univ Valencia, Hosp Clin Univ Valencia, Ctr Invest Biomed Red Epidemiol & Salud Publ CIBER, Inst Invest Sanitaria INCLIVA, Valencia, Spain
[2] Consorcio Hosp Gen Univ Valencia, Serv Urol, Valencia, Spain
[3] Conselleria San Universal & Salud Publ, Serv Anal Sistemas Informac Sanitaria, Valencia, Spain
[4] Ctr Salud Trinitat, Valencia, Spain
[5] GlaxoSmithKline, Dept Med, Madrid, Spain
[6] GlaxoSmithKline, Dept Market Access, Madrid, Spain
来源
ACTAS UROLOGICAS ESPANOLAS | 2024年 / 48卷 / 06期
关键词
Benign prostatic hyperplasia; Training program; Primary care; Real-world study; URINARY-TRACT SYMPTOMS; GUIDELINES;
D O I
10.1016/j.acuro.2023.11.006
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Introduction and objectives: A training program was developed to increase general practitioners' engagement in the optimal management of benign prostatic hyperplasia (BPH). The goal of this study was to evaluate changes in BPH management after the implementation of a training program. Material and methods: This observational retrospective cohort study was conducted between 2019 and 2020. Aggregated data were analyzed in 3 evaluation periods (2010, 2012 and 2015), addressing quality indicators for diagnosis, treatment, and treatment outcomes. Results: Overall, 118,795 patients who presented any data points were included. All quality indicators (number of IPSS and PSA determinations) increased between the first period and the last. Combination (alpha-blocker + 5-ARI) therapy was increasingly prescribed during the study periods whereas the proportion of prescriptions for single -agent alpha-blocker showed no significant differences among the periods analyzed. However, the total number of patients eligible for combination therapy who actually received this treatment was low in all periods (7.5, 17.9, and 20.1%, in 2010, 2012, and 2015, respectively). The outcome indicators revealed a decrease in referrals to the Urology unit mostly among newly diagnosed patients. Even though the proportion of patients who underwent BPH-related surgeries increased significantly from the first to the second period, the number of surgeries remained stable between the second and third periods. Conclusions: The training program had a generally positive impact on the management of BPH patients in primary care, but the overall study period may be insufficient to show an effect on some outcome indicators such as the number of surgeries. (c) 2024 The Authors. Published by Elsevier Espa & ntilde;a, S.L.U. on behalf of AEU. This is an open access article under the CC BY -NC -ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
引用
收藏
页码:461 / 469
页数:9
相关论文
共 20 条
  • [1] NEW WORDS FOR OLD - LOWER URINARY-TRACT SYMPTOMS FOR PROSTATISM
    ABRAMS, P
    [J]. BRITISH MEDICAL JOURNAL, 1994, 308 (6934) : 929 - 930
  • [2] Abrams P, 2002, NEUROUROL URODYNAM, V21, P167, DOI 10.1002/nau.10052
  • [3] Quality of life in patients with lower urinary tract symptoms associated with BPH: change over time in real-life practice according to treatment-the QUALIPROST study
    Alcaraz, Antonio
    Carballido-Rodriguez, Joaquin
    Unda-Urzaiz, Miguel
    Medina-Lopez, Rafael
    Ruiz-Cerda, Jose L.
    Rodriguez-Rubio, Federico
    Garcia-Rojo, Dario
    Brenes-Bermudez, Francisco J.
    Cozar-Olmo, Jose M.
    Baena-Gonzalez, Victor
    Manasanch, Jose
    [J]. INTERNATIONAL UROLOGY AND NEPHROLOGY, 2016, 48 (05) : 645 - 656
  • [4] Brenes Bermudez FJ, 2010, Semergen, V36, P16
  • [5] Carballido Rodriguez J, 2006, Actas Urol Esp, V30, P667
  • [6] Castineiras Fernandez J, 2010, Actas Urol Esp, V34, P24
  • [7] Impact of early vs. delayed initiation of dutasteride/tamsulosin combination therapy on the risk of acute urinary retention or BPH-related surgery in LUTS/BPH patients with moderate-to-severe symptoms at risk of disease progression
    D'Agate, Salvatore
    Chavan, Chandrashekhar
    Manyak, Michael
    Palacios-Moreno, Juan Manuel
    Oelke, Matthias
    Michel, Martin C.
    Roehrborn, Claus G.
    Della Pasqua, Oscar
    [J]. WORLD JOURNAL OF UROLOGY, 2021, 39 (07) : 2635 - 2643
  • [8] Impact of disease progression on individual IPSS trajectories and consequences of immediate versus delayed start of treatment in patients with moderate or severe LUTS associated with BPH
    D'Agate, Salvatore
    Wilson, Timothy
    Adalig, Burkay
    Manyak, Michael
    Manuel Palacios-Moreno, Juan
    Chavan, Chandrashekhar
    Oelke, Matthias
    Roehrborn, Claus
    Della Pasqua, Oscar
    [J]. WORLD JOURNAL OF UROLOGY, 2020, 38 (02) : 463 - 472
  • [9] Prevalence of lower urinary tract symptoms related with benign prostatic hyperplasia. Study of 1804 men aged 40 or older in Madrid
    Fernandez Perez, Cristina
    Moreno Sierra, Jesus
    Cano Escudero, Sara
    Fuentes Ferrer, Manuel Enrique
    Bocardo Fajardo, Gloria
    Silmi Moyano, Angel
    [J]. ACTAS UROLOGICAS ESPANOLAS, 2009, 33 (01): : 43 - 51
  • [10] What is a disease? What is the disease clinical benign prostatic hyperplasia (BPH)?
    Foo, Keong Tatt
    [J]. WORLD JOURNAL OF UROLOGY, 2019, 37 (07) : 1293 - 1296